Summit Therapeutics Inc. (SMMT) posted a GAAP net loss in the third quarter of $231.8 million or $0.31 per share, compared to a loss of $56.3 million or $0.08 per share, a year ago. Non-GAAP net loss in the third quarter was $101.0 million or $0.13 per compared to a loss of $36.9 million or $0.05 per share, prior year.
Summit also announced that, based on the results of the HARMONi clinical trial, it plans to submit a Biologics License Application in order to seek approval for ivonescimab plus chemotherapy. The company intends to submit the BLA in the fourth quarter of 2025. Summit also announced its intention to expand its ivonescimab clinical development program with an additional set of Phase III clinical studies.
Shares of Summit are down 5% in pre-market trade on Monday.
For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.